about
Bacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host-microbe interactions in intraocular infectionA dual receptor crosstalk model of G-protein-coupled signal transductionA recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritisNeurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background.Random mutagenesis of the complement factor 5a (C5a) receptor N terminus provides a structural constraint for C5a docking.Structure of the complement factor 5a receptor-ligand complex studied by disulfide trapping and molecular modeling.Review: Complement and its regulatory proteins in kidney diseases.Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.Complement-targeted therapeuticsDry age-related macular degeneration: A currently unmet clinical need.Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain reliefManipulation of the complement system for benefit in sepsis.A simple PCR-based method for the rapid genotyping of inherited fifth complement component (C5)-deficient mice.Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?Dysregulated chemokine receptor expression and chemokine-mediated cell trafficking in pediatric patients with ESRD.Targeting complement component 5a promotes vascular integrity and limits airway remodelingRheumatoid arthritis and the complement system.Platelet mediated complement activationTherapeutic targeting of the complement system in age-related macular degeneration: a review.A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.A peptide mimic of the chemotaxis inhibitory protein of Staphylococcus aureus: towards the development of novel anti-inflammatory compounds.Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system.Blood platelets activate the classical pathway of human complement.
P2860
Q26998053-69BEA08A-1035-4C8C-A77B-961C84192B86Q28473618-B7329A5E-E7BC-4544-9182-C06E35D0AF9CQ28748788-B2F5DE36-7559-439F-BB16-B566FBFA2E7BQ30481233-899B3DDC-6EFA-4F2A-A79C-CE705A82205EQ33259490-0D7C07C6-CF56-4EC1-9821-1D9D1BDFE027Q33314698-794DC909-DB22-45CF-BC06-B6A811D0CA05Q33647738-7A63C901-17B2-420D-941F-3F285FD4B8D7Q33925353-35852F35-D54F-41D3-BD22-2595C0580459Q34255011-FDAC7E5D-A5F1-4E99-8087-6731DB5FE937Q34378033-20590BAC-AEB9-451A-BD02-64C1FFFECB9AQ34601541-43B6D787-C67D-4060-8ED9-E67AC95EB899Q35829670-D16D1CC4-3025-4A4D-BCD0-7EE81E2F7E0FQ35991991-C4386E24-9761-496C-8335-2D8E60B7AA0DQ36242921-083A8E85-C4FF-4AC6-9348-FE49720D39AAQ36666771-F5345043-37D6-4FD0-89DB-0582DCDEF946Q36762599-8EE95681-CC6F-472D-A77D-EFBFFEEFCE10Q36939396-F50C986B-D86B-4C2B-A7ED-233B9694651BQ37088046-8A852A9F-F1CF-4B82-AF08-B64FC5FCC333Q37981256-D33CC528-2B8F-483A-8A0A-1B29F5160560Q40734548-B299B01F-FA78-48CD-96F3-B50795B74911Q41762604-FC1BDB61-FD47-47A7-ADDD-99D3A18ACAF3Q44995190-DCD1AC3D-D2E9-4D27-85DF-BEDAECE0D5C2Q53600476-F8A92CEA-4E5B-4B1B-A44A-F6CAA20DBA2D
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Targeting C5a: recent advances in drug discovery.
@ast
Targeting C5a: recent advances in drug discovery.
@en
type
label
Targeting C5a: recent advances in drug discovery.
@ast
Targeting C5a: recent advances in drug discovery.
@en
prefLabel
Targeting C5a: recent advances in drug discovery.
@ast
Targeting C5a: recent advances in drug discovery.
@en
P2093
P356
P1476
Targeting C5a: recent advances in drug discovery
@en
P2093
A Moriconi
A R Beccari
C Bizzarri
M Allegretti
R Di Bitondo
P304
P356
10.2174/0929867053363379
P50
P577
2005-01-01T00:00:00Z